EVISA Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:



Pharmacoepidemiology and Drug Safety


 

Status
active
Indexing
Biological Abstracts® (Thomson ISI); BIOSIS Previews® (Thomson ISI); CAB Abstracts® (CABI);
Cambridge Scientific Abstracts (CSA/CIG); Chemical Abstracts Service/SciFinder (ACS); CSA Biological Sciences Database (CSA/CIG); CSA Environmental Sciences & Pollution Management Database (CSA/CIG); Current Awareness in Biological Sciences (Elsevier); Current Contents®/Clinical Medicine (Thomson ISI); Current Index to Statistics (ASA/IMS); EMBASE/Excerpta Medica (Elsevier); Index Medicus/MEDLINE/PubMed (NLM); International Pharmaceutical Abstracts (Thomson Scientific); Journal Citation Reports/Science Edition (Thomson ISI); Science Citation Index Expanded™ (Thomson ISI); Science Citation Index® (Thomson ISI); SCOPUS (Elsevier); SIIC Databases (Sociedad Iberoamericana de Informacion Cientifica); Statistical Theory & Method Abstracts (International Statistical Institute); Web of Science® (Thomson ISI)
Subject

Source type
Journal
Publisher
ISBN ISSN
1053-8569
E ISSN
1099-1557
First volume
1
Last volume
21+
Publish city
Chichester
Homepage
Description

The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Communication.

Particular areas of interest include:

  • design, results, analysis and interpretation of post-marketing surveillance and other studies looking at specific drugs, populations and outcomes;
  • methods for detection and evaluation of drug-associated adverse events;
  • assessments of risk and benefit in drug therapy;
  • patterns of drug utilization;
  • relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
  • risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.


Related links:









Imprint     Disclaimer

© 2003 - 2010 by European Virtual Institute for Speciation Analysis ( EVISA )